Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Cancer Vaccine (NY-ESO-1) and Immunotherapy (Toripalimab) for the Treatment of Stage III/IV Platinum-Refractory or Resistant Ovarian Cancer

Trial Status: temporarily closed to accrual

This phase II trial studies how well the NY-ESO-1 vaccine works when given together with toripalimab in treating patients with stage III or IV ovarian cancer that does not respond to platinum-based chemotherapy (platinum-refractory) or whose disease progressed while receiving platinum-based chemotherapy (platinum-resistant). Toripalimab is a monoclonal antibody that enhances the immune system to better attack tumor cells, known as a programmed death receptor-1 (PD-1)-blocking antibody. NY-ESO-1 is a cancer vaccine consisting of a peptide that stimulates a cellular immune response in patients resulting in the death of tumor cells. Giving the NY-ESO-1 vaccine along with toripalimab may cause a stronger immune response and kill more tumor cells in patients with stage III/IV platinum-refractory or resistant ovarian cancer.